The US Food and Drug Administration expanded the approved indication for Medtronic plc’s Resolute Onyx zotarolimus-eluting coronary stent to include patients at high risk for bleeding who will be on dual-antiplatelet therapy for just one month following the intervention.
Resolute Onyx is the only drug-eluting stent approved by the FDA for patients who can only tolerate a one-month regimen of aspirin and an anti-clotting medication following percutaneous coronary intervention,...